Several other analysts have also commented on the company. Peel Hunt reaffirmed a buy rating and issued a GBX 302 ($4.17) price objective on shares of Puretech Health in a report on Tuesday, December 19th. Liberum Capital reaffirmed a buy rating and issued a GBX 248 ($3.43) price objective on shares of Puretech Health in a report on Thursday, November 30th. N+1 Singer reaffirmed a buy rating on shares of Puretech Health in a report on Thursday, November 30th. Finally, Jefferies Group reaffirmed a buy rating on shares of Puretech Health in a report on Friday, November 17th. Five investment analysts have rated the stock with a buy rating, The company presently has an average rating of Buy and a consensus price target of GBX 260.20 ($3.59).
Shares of Puretech Health (LON PRTC) opened at GBX 173.50 ($2.40) on Tuesday. Puretech Health has a fifty-two week low of GBX 110 ($1.52) and a fifty-two week high of GBX 183.50 ($2.54). The company has a market capitalization of $412.03 and a price-to-earnings ratio of -913.16.
Puretech Health Company Profile
PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets.
Receive News & Ratings for Puretech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puretech Health and related companies with MarketBeat.com's FREE daily email newsletter.